Evaluation and optimization of ELISA for detection of anti-Chlamydophila pneumoniae IgG and IgA in patients with coronary heart diseases.
We have evaluated and optimized a commercial enzyme-linked immunosorbent assay (ELISA; SeroCP Savyon, Israel), using the commercial microimmunofluorescence test (MIF; Labsystems; Helsinki, Finland) as reference method. This was done for the detection of anti-Chlamydophila pneumoniae IgG and IgA antibodies in patients with coronary heart disease (CHD). After optimization, a good agreement between the ELISA and MIF tests [IgG (P(0.05)=0.0008 and r=0.93) and IgA (P(0.05)=0.00072 and r=0.72)] was found. These ELISA tests proved to be a useful semiquantitative method for seroprevalence studies in CHD patients, with remarkable advantages over MIF test in terms of objective measurement, thus reproducibility, performance and interpretation.
Department of Infectious, Parasitic and Immune-mediated Diseases, Unit of Respiratory and Systemic Bacterial Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299, Rome 00161, Italy. ciervo@iss.it
Alessandra
A
Ciervo
Andrea
A
Petrucca
Paolo
P
Visca
Antonio
A
Cassone
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000907:Antibodies, Bacterial / Q000097:blood*; D002690:Chlamydia Infections / Q000097:blood / Q000175:diagnosis / Q000382:microbiology*; D016993:Chlamydophila pneumoniae / Q000276:immunology*; D003327:Coronary Disease / Q000097:blood / Q000382:microbiology*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods* / Q000592:standards; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood*; D007074:Immunoglobulin G / Q000097:blood*; D008297:Male; D008856:Microscopy, Fluorescence; D008875:Middle Aged
D000907:Antibodies, Bacterial; D007070:Immunoglobulin A; D007074:Immunoglobulin G